Cholestatic liver diseases are among the most important liver disorders that occur in infants and children, leading to devastating morbidity and accounting for over 70% of liver transplants performed during childhood, thus posing a major public health burden. Although major advances in genetics of these disorders have been made over the past decade, few therapeutic options are available. Investigation of these disorders promises to advance scientific knowledge about hepatobiliary development, hepatocyte transporters, cholangiocyte biology, genetic regulatory networks, the neonatal immune response and mechanisms of injury, as well as the discovery of biomarkers of disease and testing of new diagnostic and therapeutic strategies. With the advent of next generation sequencing and genomics/epigenomics, disease modeling mathematical paradigms and a pipeline of new potential therapies, the immediate translational impact of research in these disorders has never been greater. The 9 cholestatic disorders of the Childhood Liver Disease Research Network (ChiLDReN) have been studied in multi-centered research consortia at our Center for the past 15 years, during the last 10 years within ChiLDReN. Members of our Clinical Center at the University of Colorado Denver and Children?s Hospital Colorado have played major leadership roles as the Chair of the Steering and Executive Committees of ChiLDReN, the Chair for the CFLD studies, and Chairs of three protocols, among other roles. The objectives of this grant application in response to NIH RFA-DK-18-501 are to be chosen to be an active, collaborative and productive Clinical Center in the next version of ChiLDReN; to continue to enroll participants and complete, analyze and publish all of the ChiLDReN study protocols; to be an active participant in all new investigations, protocols and clinical trials initiated by the Network; to develop and propose new clinical and translational studies and ancillary studies that will utilize existing data and biospecimens as illustrated by our Pilot Clinical & Feasibility Trial and Scientific Translational Strategy; to maintain leadership roles and Administrative Functions of ChiLDReN and the CFLD network; and to continue to provide PFIC/BRIC/ALGS Genotyping and Respiratory Chain Analysis expertise and services. Our Scientific Research Plan will propose a Pilot & Feasibility Clinical Trial comparing the effect of two intravenous lipid emulsions on liver function in children with biliary atresia and malnutrition who require parenteral nutrition. We will also propose a Translational Science Plan that investigates the crosstalk of activated neutrophils and hepatic stellate cells in the pathogenesis of biliary atresia using specimens from participants in PROBE and BASIC. In this way, our Clinical Center will enhance and build on the ChiLDReN goals of promoting clinical and translational research on pediatric liver diseases focusing upon elucidating the pathogenesis and natural history of these disorders and developing novel diagnostic and therapeutic strategies

Public Health Relevance

This study will help to discover causes of liver disease, and develop new diagnostic tests and markers of disease activity and develop and test new treatments for infants and children with rare cholestatic liver diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01DK062453-18S1
Application #
10015473
Study Section
Special Emphasis Panel (ZDK1)
Program Officer
Doo, Edward
Project Start
2002-09-15
Project End
2024-05-31
Budget Start
2019-09-21
Budget End
2020-05-31
Support Year
18
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Pediatrics
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Loomes, Kathleen M; Spino, Cathie; Goodrich, Nathan P et al. (2018) Bone Density in Children With Chronic Liver Disease Correlates With Growth and Cholestasis. Hepatology :
Bull, Laura N; Pawlikowska, Ludmila; Strautnieks, Sandra et al. (2018) Outcomes of surgical management of familial intrahepatic cholestasis 1 and bile salt export protein deficiencies. Hepatol Commun 2:515-528
Ng, Vicky L; Sorensen, Lisa G; Alonso, Estella M et al. (2018) Neurodevelopmental Outcome of Young Children with Biliary Atresia and Native Liver: Results from the ChiLDReN Study. J Pediatr 196:139-147.e3
Alonso, Estella M; Ye, Wen; Hawthorne, Kieran et al. (2018) Impact of Steroid Therapy on Early Growth in Infants with Biliary Atresia: The Multicenter Steroids in Biliary Atresia Randomized Trial. J Pediatr 202:179-185.e4
Bezerra, Jorge A; Wells, Rebecca G; Mack, Cara L et al. (2018) BILIARY ATRESIA: Clinical and Research Challenges for the 21st Century. Hepatology :
Carey, Alexandra N; Zhang, Wujuan; Setchell, Kenneth D R et al. (2017) Hepatic MDR3 expression impacts lipid homeostasis and susceptibility to inflammatory bile duct obstruction in neonates. Pediatr Res 82:122-132
Wang, Kasper S; Tiao, Greg; Bass, Lee M et al. (2017) Analysis of surgical interruption of the enterohepatic circulation as a treatment for pediatric cholestasis. Hepatology 65:1645-1654
Sundaram, Shikha S; Mack, Cara L; Feldman, Amy G et al. (2017) Biliary atresia: Indications and timing of liver transplantation and optimization of pretransplant care. Liver Transpl 23:96-109
Tang, Vivian; Cofer, Zenobia C; Cui, Shuang et al. (2016) Loss of a Candidate Biliary Atresia Susceptibility Gene, add3a, Causes Biliary Developmental Defects in Zebrafish. J Pediatr Gastroenterol Nutr 63:524-530
Sokol, Ronald J (2016) Molecular Chaperones as Therapy for PFIC: Not So Fast! J Pediatr Gastroenterol Nutr 62:360-2

Showing the most recent 10 out of 63 publications